 - Patients with unresected metastases from colorectal cancer; patients may be either untreated with chemotherapy or currently receiving first-line 5-FU based chemotherapy folinic acid-fluorouracil-irinotecan hydrochloride FOLFIRI, capecitabine-irinotecan hydrochloride CAPIRI, fluorouracil-leucovorin calcium-oxaliplatin FOLFOX, or capecitabine-oxaliplatin CAPOX with or without bevacizumab within 10 months of beginning ADAPT therapy with at least stable disease radiographically; patients who received prior adjuvant chemotherapy with 5-FU, capecitabine, or FOLFOX are eligible if adjuvant therapy was completed greater than 6 months ago 